The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
Jonathan T. Seal, Stephen J. Atkinson, Helen Aylott, Paul Bamborough, Chun‐wa Chung, Royston C. B. Copley, Laurie Gordon, Paola Grandi, James R. Gray, Lee A. Harrison, Thomas G. Hayhow, Matthew Lindon, Cassie Messenger, Anne‐Marie Michon, Darren J. Mitchell, Alex Preston, Rab K. Prinjha, Inmaculada Rioja, S. Taylor, Ian D. Wall, Robert J. Watson, James M. Woolven, Emmanuel H. Demont
Abstract
(GSK549), which showed an anti-inflammatory phenotype in human whole blood, confirming their cellular target engagement. Excellent broad selectivity, developability, and in vivo oral pharmacokinetics characterize these tools, which we hope will be of broad utility to the field of epigenetics research.
Topics & Concepts
BromodomainChemistryEpigeneticsLigand (biochemistry)Homology modelingIn vivoSmall moleculeStereochemistrySelectivityBRD4Fragment (logic)Computational biologyCombinatorial chemistryBiochemistryEnzymeReceptorGeneticsGeneBiologyComputer scienceProgramming languageCatalysisProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsHIV Research and Treatment